Skip to main content

Table 1 Patient demographics

From: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

 HER-2 negative
ER+ and/or PgR+ER− PgR−
n182
Age, years, median (range)52 (42–76)56.5 (48–65)
Race, n (%)
 White15 (83.3)2 (100)
 Black1 (5.6)0
 Asian1 (5.6)0
 Multiple1 (5.6)0
Weight, kg, median (range)68.25 (55.3–97.2)68.10 (56.7–79.5)
Clinical tumor stage
 IA4 (22.2)1 (50)
 IB3 (16.7)0
 T2N0M0 (IIa)7 (38.9)1 (50)
 T2N1M0 (IIb)2 (11.1)0
 T3N0M0 (IIb)2 (11.1)0